How AI, Analytics, and Collaboration Can Solve Specialty Drug Spending Challenges
Nicole Bulochnik, Abarca Senior Vice President of Drug Value Strategy, explained how AI, analytics, and cross-sector collaboration can transform specialty drug costs.
presented by
Free Market Health Acquires Beeline Rx to Streamline Specialty Prior Auth
Free Market Health acquired Beeline Rx, a tech company that streamlines the prior authorization process for specialty drugs.
presented by
Could QuantalX’s Device Make Managing Brain Health Easier?
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
What Drives Specialty Medication Enrollment Conversions? It’s Not What You Think.
We can no longer simply worry about the enrollment form as the only hurdle in therapy initiation. We must view the entire patient journey as an interconnected set of challenges that need solving. And I believe achieving that goal is within reach.
Which Drugs Are Driving Next Year’s 3.42% Increase in Hospital Pharmacy Spend?
Hospitals’ pharmacy spending is projected to rise by 3.42% next year, according to a new report. Specialty drugs, including Ozempic and Humira, as well as neurology medications are the primary drivers of this increase in pharmacy expenses.
Lyfegen raises $8M for its value-based drug contracting platform
Lyfegen, a startup that provides software for value-based drug contracting, recently raised $8 million in an oversubscribed Series A financing round. With the new funds, the company — which is based in Switzerland and New York — plans to expand its presence in the U.S., where drug costs are the highest in the world.
Inflated savings, hidden costs: How vendors who “carve-out” specialty benefits fail to deliver promised value
In recent years, a number of niche vendors have entered the market, promising significant savings for payers if they “carve-out” specialty pharmacy services from integrated pharmacy benefits management (PBM). While the savings they claim to provide sound undeniably attractive, they are often greatly exaggerated.
As Healthcare and Biopharma Companies Embrace AI, Insurance Underwriters See Risks and Opportunities
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
Focus on specialty drugs reflects ‘cyclical nature’ of biopharma, industry veteran says
Adam Schechter, an adviser to Merck's CEO, said at the Veeva Summit Tuesday that many primary care diseases - such as cardiovascular disease and Alzheimer's - still have significant unmet needs.
PwC Infographic: Costs from specialty drugs skyrocket
Specialty drugs are outpacing traditional drugs in a major way, a new PwC report says. This is a real concern in terms of controlling overall medical costs.
Specialty drugs are driving up the U.S. medication spend – indeed a prime revenue opp
Need proof that orphan indication’s the way to go? The demand for specialty medications – and their premium pricing – is driving up the total American spend on medication, a new study says. A revenue darling for most budding biotechs, specialty drugs acccounted for $124.1 billion of medication dollars spent, out of a total of […]
The economics of high-cost specialty drugs, illustrated
Specialty drugs – the costly medications used to treat complex disease like cancer and Hepatitis C – have become a hot-button topic given the fact that healthcare spending is perpetually on the rise. After a five-year contraction in healthcare spending growth, medical costs are projected to climb another 6.8 percent in 2015, according to the Health […]
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.